U.S. patent application number 13/091518 was filed with the patent office on 2011-10-27 for compositions.
This patent application is currently assigned to NANOMR, INC.. Invention is credited to Eddie W. Adams, Lisa-Jo Ann Clarizia, Sergey A. Dryga, Victor C. Esch.
Application Number | 20110262932 13/091518 |
Document ID | / |
Family ID | 44816109 |
Filed Date | 2011-10-27 |
United States Patent
Application |
20110262932 |
Kind Code |
A1 |
Esch; Victor C. ; et
al. |
October 27, 2011 |
COMPOSITIONS
Abstract
The invention generally relates to compositions that include
magnetic particles bound to pathogens in a body fluid.
Inventors: |
Esch; Victor C.;
(Albuquerque, NM) ; Dryga; Sergey A.; (Rio Rancho,
NM) ; Clarizia; Lisa-Jo Ann; (Albuquerque, NM)
; Adams; Eddie W.; (Albuquerque, NM) |
Assignee: |
NANOMR, INC.
Albuquerque
NM
|
Family ID: |
44816109 |
Appl. No.: |
13/091518 |
Filed: |
April 21, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61326588 |
Apr 21, 2010 |
|
|
|
Current U.S.
Class: |
435/7.1 ;
428/402; 435/252.1; 530/391.3 |
Current CPC
Class: |
B01L 2200/0647 20130101;
G01N 2446/20 20130101; Y10T 428/2982 20150115; C12Q 1/6806
20130101; C12N 13/00 20130101; C12Q 1/689 20130101; G01N 33/56911
20130101; G01N 33/54326 20130101; G01N 33/54333 20130101; C07K 1/22
20130101; G01N 2333/195 20130101; C07K 16/1267 20130101; B01L
2400/043 20130101; C12Q 1/6806 20130101; C12Q 2565/629 20130101;
C12Q 2563/143 20130101 |
Class at
Publication: |
435/7.1 ;
435/252.1; 530/391.3; 428/402 |
International
Class: |
G01N 33/569 20060101
G01N033/569; C01G 49/10 20060101 C01G049/10; C01G 49/08 20060101
C01G049/08; C12N 1/20 20060101 C12N001/20; C07K 16/12 20060101
C07K016/12 |
Claims
1. A composition comprising a pathogen to which a plurality of
magnetic particles are attached, said particles having at least
about 70% magnetic material by weight, and wherein said particles
are sufficient in number for specific detection of said pathogen
over background.
2. The composition of claim 1, wherein the particles are about 200
nm in diameter.
3. The composition of claim 1, wherein the magnetic material is
Fe.sub.3O.sub.4 or FePF.
4. The composition of claim 1, wherein the pathogen is a
bacterium.
5. The composition of claim 4, wherein the bacterium is a bacterium
found in human blood.
6. The composition of claim 1, wherein the particles are conjugated
with antibodies.
7. The composition of claim 6, wherein the antibodies are
monoclonal antibodies.
8. The composition of claim 6, wherein the antibodies are
polyclonal antibodies.
9. A blood sample comprising a plurality of magnetic particles
conjugated to pathogen-specific antibodies, wherein said particles
comprise from about 65% to about 99.9% magnetic material by weight;
and wherein said particles confer a high magnetic moment on
pathogen present in said sample upon attachment to said
pathogen.
10. The composition of claim 9, wherein the particles are about 200
nm in diameter.
11. The composition of claim 9, wherein the magnetic material is
Fe.sub.3O.sub.4 or FePF.
12. The composition of claim 9, wherein the pathogen is a
bacterium.
13. The composition of claim 12, wherein the bacterium is a
bacterium found in human blood.
14. The composition of claim 9, wherein the antibodies are
monoclonal antibodies.
15. The composition of claim 9, wherein the antibodies are
polyclonal antibodies.
16. A blood sample comprising a plurality of antibody conjugated
particles, said particles comprising at least about 65% magnetic
material by weight.
17. The composition of claim 16, wherein the particles are about
200 nm in diameter.
18. The composition of claim 16, wherein the magnetic material is
Fe.sub.3O.sub.4 or FePF.
19. A magnetic particle, wherein the particle comprises at least
about 70% magnetic material and is about 200 nm in diameter.
20. The particle of claim 19, wherein the magnetic material is
Fe.sub.3O.sub.4 or FePF.
Description
RELATED APPLICATION
[0001] The present application claims the benefit of and priority
to U.S. provisional patent application Ser. No. 61/326,588, filed
Apr. 21, 2010, the content of which is incorporated by reference
herein in its entirety.
FIELD OF THE INVENTION
[0002] The invention generally relates to compositions that include
magnetic particles bound to pathogens in a body fluid.
BACKGROUND
[0003] Blood-borne pathogens are a significant healthcare problem.
A delayed or improper diagnosis of a bacterial infection can result
in sepsis, a serious, and often deadly, inflammatory response to
the infection. Sepsis is the 10.sup.th leading cause of death in
the United States. Early detection of bacterial infections in blood
is the key to preventing the onset of sepsis. Traditional methods
of detection and identification of blood-borne infection include
blood culture and antibiotic susceptibility assays. Those methods
typically require culturing cells, which can be expensive and can
take as long as 72 hours. Often, septic shock will occur before
cell culture results can be obtained.
[0004] Alternative methods for detection of pathogens, particularly
bacteria, have been described by others. Those methods include
molecular detection methods, antigen detection methods, and
metabolite detection methods. Molecular detection methods, whether
involving hybrid capture or polymerase chain reaction (PCR),
require high concentrations of purified DNA for detection. Both
antigen detection and metabolite detection methods also require a
relatively large amount of bacteria and have high limit of
detection (usually>10.sup.4 CFU/mL), thus requiring an
enrichment step prior to detection. This incubation/enrichment
period is intended to allow for the growth of bacteria and an
increase in bacterial cell numbers to more readily aid in
identification. In many cases, a series of two or three separate
incubations is needed to isolate the target bacteria. However, such
enrichment steps require a significant amount of time (e.g., at
least a few days to a week) and can potentially compromise test
sensitivity by killing some of the cells sought to be measured.
[0005] There is a need for methods for isolating target analytes,
such as bacteria, from a sample, such as a blood sample, without an
additional enrichment step. There is also a need for methods of
isolating target analytes that are fast and sensitive in order to
provide data for patient treatment decisions in a clinically
relevant time frame.
SUMMARY
[0006] The present invention relates to isolating unknown pathogens
in a biological sample. The invention allows the rapid detection of
unknown pathogen at very low levels in the sample; thus enabling
early and accurate detection and identification of the pathogen.
The invention is carried out using magnetic particles having a
particular percentage of magnetic material by weight and being
functionalized for binding to pathogens. Compositions of the
invention may be introduced to a body fluid sample in order to
create a mixture. The mixture is incubated to allow the particles
to bind to any pathogen in the body fluid, and a magnetic field is
applied to capture pathogen/magnetic particle complexes on a
surface. Optionally, the surface can be washed with a wash solution
that reduces particle aggregation, thereby isolating
pathogen/magnetic particle complexes. A particular advantage of
compositions of the invention is for capture and isolation of
bacteria and fungi directly from blood samples at low
concentrations that are present in many clinical samples (as low as
1 CFU/ml of bacteria in a blood sample).
[0007] In certain aspects, the invention provides a composition
including a pathogen to which a plurality of magnetic particles are
attached, the particles having at least about 70% magnetic material
by weight, and wherein the particles are sufficient in number for
specific detection of the pathogen over background.
[0008] Compositions of the invention may use any type of magnetic
particle. Magnetic particles generally fall into two broad
categories. The first category includes particles that are
permanently magnetizable, or ferromagnetic; and the second category
includes particles that demonstrate bulk magnetic behavior only
when subjected to a magnetic field. The latter are referred to as
magnetically responsive particles. Materials displaying
magnetically responsive behavior are sometimes described as
superparamagnetic. However, materials exhibiting bulk ferromagnetic
properties, e.g., magnetic iron oxide, may be characterized as
superparamagnetic when provided in crystals of about 30 nm or less
in diameter. Larger crystals of ferromagnetic materials, by
contrast, retain permanent magnet characteristics after exposure to
a magnetic field and tend to aggregate thereafter due to strong
particle-particle interaction. In certain embodiments, the
particles are superparamagnetic particles. In other embodiments,
the magnetic particles include at least 70% superparamagnetic
particles by weight. In certain embodiments, the superparamagnetic
particles are from about 100 nm to about 250 nm in diameter. In
particular embodiments, the particles are about 20 nm in diameter.
In certain embodiments, the magnetic particle is an iron-containing
magnetic particle. In other embodiments, the magnetic particle
includes iron oxide (Fe.sub.3O.sub.4) or iron platinum (FePF).
[0009] The particles may be conjugated with any moiety that allows
for specific binding of pathogen. The moiety may be any capture
moiety known in the art, such as an antibody, an aptamer, a nucleic
acid, a protein, a receptor, a phage or a ligand. In particular
embodiments, the target-specific binding moiety is an antibody. In
certain embodiments, the antibody is specific for bacteria. In
other embodiments, the antibody is specific for fungi. The
antibodies conjugated to the particles may be either monoclonal or
polyclonal antibodies.
[0010] The pathogen may be any disease producing agent. Exemplary
pathogens include bacteria, fungi, protein, a cell, a virus, a
nucleic acid, a receptor, a ligand, or any molecule known in the
art. In certain embodiments, the pathogen is a bacteria. The
bacteria may be gram positive or gram negative. In particular
embodiments, the bacteria is one that is found in human blood.
Exemplary bacterial species to which compositions of the invention
may bind include E. coli, Listeria, Clostridium, Mycobacterium,
Shigella, Borrelia, Campylobacter, Bacillus, Salmonella,
Staphylococcus, Enterococcus, Pneumococcus, Streptococcus, and a
combination thereof.
[0011] Another aspect of the invention provides a blood sample
including a plurality of magnetic particles conjugated to
pathogen-specific antibodies, in which the particles include from
about 65% to about 99.9% magnetic material by weight, and the
particles confer a high magnetic moment on pathogen present in the
sample upon attachment to said pathogen.
[0012] Another aspect of the invention provides a blood sample
including a plurality of antibody conjugated particles, the
particles including at least about 65% magnetic material by
weight.
[0013] To facilitate detection of the magnetic particle complexes,
the particles may be differently labeled. Any detectable label may
be used with compositions of the invention, such as fluorescent
labels, radiolabels, enzymatic labels, and others. In particular
embodiments, the detectable label is an optically-detectable label,
such as a fluorescent label. Exemplary fluorescent labels include
Cy3, Cy5, Atto, cyanine, rhodamine, fluorescien, coumarin, BODIPY,
alexa, and conjugated multi-dyes.
DETAILED DESCRIPTION
[0014] The invention generally relates to compositions that include
magnetic particles bound to pathogens in a body fluid. Certain
fundamental technologies and principles are associated with binding
magnetic materials to target entities and subsequently separating
by use of magnet fields and gradients. Such fundamental
technologies and principles are known in the art and have been
previously described, such as those described in Janeway
(Immunobiology, 6.sup.th edition, Garland Science Publishing), the
content of which is incorporated by reference herein in its
entirety.
[0015] Compositions of the invention may use any type of magnetic
particle. Production of magnetic particles and particles for use
with the invention are known in the art. See for example Giaever
(U.S. Pat. No. 3,970,518), Senyi et al. (U.S. Pat. No. 4,230,685),
Dodin et al. (U.S. Pat. No. 4,677,055), Whitehead et al. (U.S. Pat.
No. 4,695,393), Benjamin et al. (U.S. Pat. No. 5,695,946), Giaever
(U.S. Pat. No. 4,018,886), Rembaum (U.S. Pat. No. 4,267,234),
Molday (U.S. Pat. No. 4,452,773), Whitehead et al. (U.S. Pat. No.
4,554,088), Forrest (U.S. Pat. No. 4,659,678), Liberti et al. (U.S.
Pat. No. 5,186,827), Own et al. (U.S. Pat. No. 4,795,698), and
Liberti et al. (WO 91/02811), the content of each of which is
incorporated by reference herein in its entirety.
[0016] Magnetic particles generally fall into two broad categories.
The first category includes particles that are permanently
magnetizable, or ferromagnetic; and the second category includes
particles that demonstrate bulk magnetic behavior only when
subjected to a magnetic field. The latter are referred to as
magnetically responsive particles. Materials displaying
magnetically responsive behavior are sometimes described as
superparamagnetic. However, materials exhibiting bulk ferromagnetic
properties, e.g., magnetic iron oxide, may be characterized as
superparamagnetic when provided in crystals of about 30 nm or less
in diameter. Larger crystals of ferromagnetic materials, by
contrast, retain permanent magnet characteristics after exposure to
a magnetic field and tend to aggregate thereafter due to strong
particle-particle interaction. In certain embodiments, the
particles are superparamagnetic particles. In certain embodiments,
the magnetic particle is an iron containing magnetic particle. In
other embodiments, the magnetic particle includes iron oxide
(Fe.sub.3O.sub.4) or iron platinum (FePF).
[0017] In certain embodiments, the magnetic particles include at
least about 10% magnetic material by weight, at least about 20%
magnetic material by weight, at least about 30% magnetic material
by weight, at least about 40% magnetic material by weight, at least
about 50% magnetic material by weight, at least about 60% magnetic
material by weight, at least about 70% magnetic material by weight,
at least about 80% magnetic material by weight, at least about 90%
magnetic material by weight, at least about 95% magnetic material
by weight, or at least about 99% magnetic material by weight. In a
particular embodiment, the magnetic particles include at least
about 70% superparamagnetic particles by weight. In other
embodiments, the magnetic particles are from about 65% to about
99.9% magnetic material by weight.
[0018] In certain embodiments, the magnetic particles are less than
100 nm in diameter. In other embodiments, the magnetic particles
are about 150 nm in diameter, are about 200 nm in diameter, are
about 250 nm in diameter, are about 300 nm in diameter, are about
350 nm in diameter, are about 400 nm in diameter, are about 500 nm
in diameter, or are about 1000 nm in diameter. In a particular
embodiment, the magnetic particles are from about 100 nm to about
250 nm in diameter. In certain embodiments, the particles are 200
nm in diameter. In certain embodiments, the magnetic particles at
about 70% magnetic material and 200 nm in diameter. In other
embodiments, the magnetic particles are from about 65% to about
99.9% magnetic material by weight and are 200 nm in diameter.
[0019] In certain embodiments, the particles are particles (e.g.,
nanoparticles) that incorporate magnetic materials, or magnetic
materials that have been functionalized, or other configurations as
are known in the art. In certain embodiments, nanoparticles may be
used that include a polymer material that incorporates magnetic
material(s), such as nanometal material(s). When those nanometal
material(s) or crystal(s), such as Fe.sub.3O.sub.4, are
superparamagnetic, they may provide advantageous properties, such
as being capable of being magnetized by an external magnetic field,
and demagnetized when the external magnetic field has been removed.
This may be advantageous for facilitating sample transport into and
away from an area where the sample is being processed without undue
particle aggregation.
[0020] One or more or many different nanometal(s) may be employed,
such as Fe.sub.3O.sub.4, FePt, or Fe, in a core-shell configuration
to provide stability, and/or various others as may be known in the
art. In many applications, it may be advantageous to have a
nanometal having as high a saturated moment per volume as possible,
as this may maximize gradient related forces, and/or may enhance a
signal associated with the presence of the particles. It may also
be advantageous to have the volumetric loading in a particle be as
high as possible, for the same or similar reason(s). In order to
maximize the moment provided by a magnetizable nanometal, a certain
saturation field may be provided. For example, for Fe.sub.3O.sub.4
superparamagnetic particles, this field may be on the order of
about 0.3 T.
[0021] The size of the nanometal containing particle may be
optimized for a particular application, for example, maximizing
moment loaded upon a target, maximizing the number of particles on
a target with an acceptable detectability, maximizing desired
force-induced motion, and/or maximizing the difference in attached
moment between the labeled target and non-specifically bound
targets or particle aggregates or individual particles. While
maximizing is referenced by example above, other optimizations or
alterations are contemplated, such as minimizing or otherwise
desirably affecting conditions.
[0022] In an exemplary embodiment, a polymer particle containing 80
wt % Fe.sub.3O.sub.4 superparamagnetic particles, or for example,
90 wt % or higher superparamagnetic particles, is produced by
encapsulating superparamagnetic particles with a polymer coating to
produce a particle having a diameter of about 250 nm. In another
exemplary embodiment, a polymer particle containing 70 wt %
Fe.sub.3O.sub.4 superparamagnetic particles, or for example, 65 to
99.9 wt % superparamagnetic particles, is produced by encapsulating
superparamagnetic particles with a polymer coating to produce a
particle having a diameter of about 200 nm.
[0023] Magnetic particles for use with methods of the invention
have a target-specific binding moiety that allows for the particles
to specifically bind the pathogen. The target-specific moiety may
be any molecule known in the art and will depend on the pathogen to
be captured and isolated. Exemplary target-specific binding
moieties include nucleic acids, proteins, ligands, antibodies,
aptamers, and receptors.
[0024] In particular embodiments, the target-specific binding
moiety is an antibody, such as an antibody that binds a particular
bacterium. General methodologies for antibody production, including
criteria to be considered when choosing an animal for the
production of antisera, are described in Harlow et al. (Antibodies,
Cold Spring Harbor Laboratory, pp. 93-117, 1988). For example, an
animal of suitable size such as goats, dogs, sheep, mice, or camels
are immunized by administration of an amount of immunogen, such the
target bacteria, effective to produce an immune response. An
exemplary protocol is as follows. The animal is injected with 100
milligrams of antigen resuspended in adjuvant, for example Freund's
complete adjuvant, dependent on the size of the animal, followed
three weeks later with a subcutaneous injection of 100 micrograms
to 100 milligrams of immunogen with adjuvant dependent on the size
of the animal, for example Freund's incomplete adjuvant. Additional
subcutaneous or intraperitoneal injections every two weeks with
adjuvant, for example Freund's incomplete adjuvant, are
administered until a suitable titer of antibody in the animal's
blood is achieved. Exemplary titers include a titer of at least
about 1:5000 or a titer of 1:100,000 or more, i.e., the dilution
having a detectable activity. The antibodies are purified, for
example, by affinity purification on columns containing protein G
resin or target-specific affinity resin.
[0025] The technique of in vitro immunization of human lymphocytes
is used to generate monoclonal antibodies. Techniques for in vitro
immunization of human lymphocytes are well known to those skilled
in the art. See, e.g., Inai, et al., Histochemistry, 99(5):335 362,
May 1993; Mulder, et al., Hum. Immunol., 36(3):186 192, 1993;
Harada, et al., J. Oral Pathol. Med., 22(4):145 152, 1993; Stauber,
et al., J. Immunol. Methods, 161(2):157 168, 1993; and
Venkateswaran, et al., Hybridoma, 11(6) 729 739, 1992. These
techniques can be used to produce antigen-reactive monoclonal
antibodies, including antigen-specific IgG, and IgM monoclonal
antibodies.
[0026] Any antibody or fragment thereof having affinity and
specific for the bacteria of interest is within the scope of the
invention provided herein. Immunomagnetic particles against
Salmonella are provided in Vermunt et al. (J. Appl. Bact. 72:112,
1992). Immunomagnetic particles against Staphylococcus aureus are
provided in Johne et al. (J. Clin. Microbiol. 27:1631, 1989).
Immunomagnetic particles against Listeria are provided in Skjerve
et al. (Appl. Env. Microbiol. 56:3478, 1990). Immunomagnetic
particles against Escherichia coli are provided in Lund et al. (J.
Clin. Microbiol. 29:2259, 1991).
[0027] Methods for attaching the target-specific binding moiety to
the magnetic particle are known in the art. Coating magnetic
particles with antibodies is well known in the art, see for example
Harlow et al. (Antibodies, Cold Spring Harbor Laboratory, 1988),
Hunter et al. (Immunoassays for Clinical Chemistry, pp. 147-162,
eds., Churchill Livingston, Edinborough, 1983), and Stanley
(Essentials in Immunology and Serology, Delmar, pp. 152-153, 2002).
Such methodology can easily be modified by one of skill in the art
to bind other types of target-specific binding moieties to the
magnetic particles. Certain types of magnetic particles coated with
a functional moiety are commercially available from Sigma-Aldrich
(St. Louis, Mo.).
[0028] Since each set of particles is conjugated with antibodies
having different specificities for different pathogens,
compositions of the invention may be provided such that each set of
antibody conjugated particles is present at a concentration
designed for detection of a specific pathogen in the sample. In
certain embodiments, all of the sets are provided at the same
concentration. Alternatively, the sets are provided at different
concentrations. For example, compositions may be designed such that
sets that bind gram positive bacteria are added to the sample at a
concentration of 2.times.10.sup.9 particles per/ml, while sets that
bind gram negative bacteria are added to the sample at a
concentration of 4.times.10.sup.9 particles per/ml. Compositions of
the invention are not affected by antibody cross-reactivity.
However, in certain embodiments, sets are specifically designed
such that there is no cross-reactivity between different antibodies
and different sets.
[0029] Compositions of the invention may be designed to isolate
only gram positive bacteria from a sample. Alternatively,
compositions of the invention may be designed to isolate only gram
negative bacteria from a sample. In certain embodiments,
compositions of the invention are designed to isolate both gram
positive and gram negative bacteria from a sample. Such
compositions allow for isolation of essentially all bacteria from a
sample.
[0030] In still other embodiments, compositions are designed to
isolate specific pathogen from a sample. Exemplary bacterial
species that may be captured and isolated by methods of the
invention include E. coli, Listeria, Clostridium, Mycobacterium,
Shigella, Borrelia, Campylobacter, Bacillus, Salmonella,
Staphylococcus, Enterococcus, Pneumococcus, Streptococcus, and a
combination thereof. These sets can be mixed together to isolate
for example, E. coli and Listeria; or E. coli, Listeria, and
Clostridium; or Mycobacterium, Campylobacter, Bacillus, Salmonella,
and Staphylococcus, etc. Any combination of sets may be used and
compositions of the invention will vary depending on the suspected
pathogen or pathogens to be isolated.
[0031] Capture of a wide range of target microorganisms
simultaneously can be achieved by utilizing antibodies specific to
target class, such as pan-Gram-positive antibodies,
pan-Gran-negative antibodies or antibodies specific to a subset of
organisms of a certain class. Further, expanded reactivity can be
achieved by mixing particles of different reactivity. It was shown
in our experiments that addition of high concentration of
non-specific particles does not interfere with the capture
efficiency of target-specific particles. Similarly, several
different particle preparations can be combined to allow for the
efficient capture of desired pathogens. In certain embodiments the
particles can be utilized at a concentration between
.times.10.sup.8 and 5.times.10.sup.10 particles/mL.
[0032] In certain embodiments the expanded coverage can be provided
by mixing antibodies with different specificity before attaching
them to magnetic particles. Purified antibodies can be mixed and
conjugated to activated magnetic particle using standard methods
known in the art.
[0033] To facilitate detection of the different sets of
pathogen/magnetic particle complexes the particles may be
differently labeled. Any detectable label may be used with
compositions of the invention, such as fluorescent labels,
radiolabels, enzymatic labels, and others. The detectable label may
be directly or indirectly detectable. In certain embodiments, the
exact label may be selected based, at least in part, on the
particular type of detection method used. Exemplary detection
methods include radioactive detection, optical absorbance
detection, e.g., UV-visible absorbance detection, optical emission
detection, e.g., fluorescence; phosphorescence or
chemiluminescence; Raman scattering. Preferred labels include
optically-detectable labels, such as fluorescent labels. Examples
of fluorescent labels include, but are not limited to,
4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic acid; acridine
and derivatives: acridine, acridine isothiocyanate;
5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS);
4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate;
N-(4-anilino-1-naphthyl)maleimide; anthranilamide; BODIPY;
Brilliant Yellow; coumarin and derivatives; coumarin,
7-amino-4-methylcoumarin (AMC, Coumarin 120),
7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanine dyes;
cyanosine; 4',6-diaminidino-2-phenylindole (DAPI);
5'5''-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red);
7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin;
diethylenetriamine pentaacetate;
4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid;
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid;
5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS,
dansylchloride); 4-dimethylaminophenylazophenyl-4'-isothiocyanate
(DABITC); eosin and derivatives; eosin, eosin isothiocyanate,
erythrosin and derivatives; erythrosin B, erythrosin,
isothiocyanate; ethidium; fluorescein and derivatives;
5-carboxyfluorescein (FAM),
5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF),
2',7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein, fluorescein,
fluorescein isothiocyanate, QFITC, (XRITC); fluorescamine; IR144;
IR1446; Malachite Green isothiocyanate; 4-methylumbelliferoneortho
cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red;
B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives:
pyrene, pyrene butyrate, succinimidyl 1-pyrene; butyrate quantum
dots; Reactive Red 4 (Cibacron.TM. Brilliant Red 3B-A) rhodamine
and derivatives: 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine
(R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod),
rhodamine B, rhodamine 123, rhodamine X isothiocyanate,
sulforhodamine B, sulforhodamine 101, sulfonyl chloride derivative
of sulforhodamine 101 (Texas Red);
N,N,N',N'tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl
rhodamine; tetramethyl rhodamine isothiocyanate (TRITC);
riboflavin; rosolic acid; terbium chelate derivatives; Atto dyes,
Cy3; Cy5; Cy5.5; Cy7; IRD 700; IRD 800; La Jolta Blue; phthalo
cyanine; and naphthalo cyanine. Preferred fluorescent labels are
cyanine-3 and cyanine-5. Labels other than fluorescent labels are
contemplated by the invention, including other optically-detectable
labels. Methods of linking fluorescent labels to magnetic particles
or antibodies are known in the art.
[0034] Conjugated magnetic particles of the invention may be used
with any heterogeneous sample. In particular embodiments,
compositions of the invention are used to isolate a pathogen from
body fluid. A body fluid refers to a liquid material derived from,
for example, a human or other mammal. Such body fluids include, but
are not limited to, mucus, blood, plasma, serum, serum derivatives,
bile, phlegm, saliva, sweat, amniotic fluid, mammary fluid, urine,
sputum, and cerebrospinal fluid (CSF), such as lumbar or
ventricular CSF. A body fluid may also be a fine needle aspirate. A
body fluid also may be media containing cells or biological
material.
[0035] In particular embodiments, the fluid is blood. Using
compositions of the invention, bacteria in a blood sample may be
isolated and detected at a level as low as or even lower than 1
CFU/ml. Blood may be collected in a container, such as a blood
collection tube (e.g., VACUTAINER, test tube specifically designed
for venipuncture, commercially available from Becton, Dickinson and
company). In certain embodiments, a solution is added that prevents
or reduces aggregation of endogenous aggregating factors, such as
heparin in the case of blood.
[0036] The blood sample is then mixed with compositions of the
invention to generate a mixture that is allowed to incubate such
that the compositions of the invention bind to at least one
bacterium in the blood sample. In particular embodiments, the
magnetic particles mixed with the blood sample include from about
65% to about 99.9% magnetic material by weight, particular at least
about 65% magnetic material by weight or at least about 70%
magnetic material by weight. The particles may also be from about
100 nm to about 250 nm in diameter, particularly 200 nm in
diameter. The magnetic material may be Fe.sub.3O.sub.4 or FePF. The
particles may be conjugated with either monoclonal or polyclonal
antibodies.
[0037] The type or types of bacteria that will bind compositions of
the invention will depend on the design of the composition, i.e.,
which antibody conjugated particles are used. The mixture is
allowed to incubate for a sufficient time to allow for the
composition to bind to the pathogen in the blood. The process of
binding the composition to the pathogen associates a magnetic
moment with the pathogen, and thus allows the pathogen to be
manipulated through forces generated by magnetic fields upon the
attached magnetic moment.
[0038] In general, incubation time will depend on the desired
degree of binding between the pathogen and the compositions of the
invention (e.g., the amount of moment that would be desirably
attached to the pathogen), the amount of moment per target, the
amount of time of mixing, the type of mixing, the reagents present
to promote the binding and the binding chemistry system that is
being employed. Incubation time can be anywhere from about 5
seconds to a few days. Exemplary incubation times range from about
10 seconds to about 2 hours. Binding occurs over a wide range of
temperatures, generally between 15.degree. C. and 40.degree. C.
[0039] In certain embodiments, a buffer solution is added to the
sample along with the compositions of the invention. An exemplary
buffer includes Tris(hydroximethyl)-aminomethane hydrochloride at a
concentration of about 75 mM. It has been found that the buffer
composition, mixing parameters (speed, type of mixing, such as
rotation, shaking etc., and temperature) influence binding. It is
important to maintain osmolality of the final solution (e.g.,
blood+buffer) to maintain high label efficiency. In certain
embodiments, buffers used in methods of the invention are designed
to prevent lysis of blood cells, facilitate efficient binding of
targets with magnetic particles and to reduce formation of particle
aggregates. It has been found that the buffer solution containing
300 mM NaCl, 75 mM Tris-HCl pH 8.0 and 0.1% Tween 20 meets these
design goals.
[0040] Without being limited by any particular theory or mechanism
of action, it is believed that sodium chloride is mainly
responsible for maintaining osmolality of the solution and for the
reduction of non-specific binding of magnetic particle through
ionic interaction. Tris(hydroximethyl)-aminomethane hydrochloride
is a well established buffer compound frequently used in biology to
maintain pH of a solution. It has been found that 75 mM
concentration is beneficial and sufficient for high binding
efficiency. Likewise, Tween 20 is widely used as a mild detergent
to decrease nonspecific attachment due to hydrophobic interactions.
Various assays use Tween 20 at concentrations ranging from 0.01% to
1%. The 0.1% concentration appears to be optimal for the efficient
labeling of bacteria, while maintaining blood cells intact.
[0041] Additional compounds can be used to modulate the capture
efficiency by blocking or reducing non-specific interaction with
blood components and either magnetic particles or pathogens. For
example, chelating compounds, such as EDTA or EGTA, can be used to
prevent or minimize interactions that are sensitive to the presence
of Ca.sup.2+ or Mg.sup.2+ ions.
[0042] An alternative approach to achieve high binding efficiency
while reducing time required for the binding step is to use static
mixer, or other mixing devices that provide efficient mixing of
viscous samples at high flow rates, such as at or around 5 mL/min.
In one embodiment, the sample is mixed with binding buffer in ratio
of, or about, 1:1, using a mixing interface connector. The diluted
sample then flows through a mixing interface connector where it is
mixed with target-specific nanoparticles. Additional mixing
interface connectors providing mixing of sample and
antigen-specific nanoparticles can be attached downstream to
improve binding efficiency. The combined flow rate of the labeled
sample is selected such that it is compatible with downstream
processing.
[0043] After binding of the compositions of the invention to the
pathogen in the sample to form pathogen/magnetic particle
complexes, a magnetic field is applied to the mixture to capture
the complexes on a surface. Components of the mixture that are not
bound to magnetic particles will not be affected by the magnetic
field and will remain free in the mixture. Methods and apparatuses
for separating target/magnetic particle complexes from other
components of a mixture are known in the art. For example, a steel
mesh may be coupled to a magnet, a linear channel or channels may
be configured with adjacent magnets, or quadrapole magnets with
annular flow may be used. Other methods and apparatuses for
separating target/magnetic particle complexes from other components
of a mixture are shown in Rao et al. (U.S. Pat. No. 6,551,843),
Liberti et al. (U.S. Pat. No. 5,622,831), Hatch et al. (U.S. Pat.
No. 6,514,415), Benjamin et al. (U.S. Pat. No. 5,695,946), Liberti
et al. (U.S. Pat. No. 5,186,827), Wang et al. (U.S. Pat. No.
5,541,072), Liberti et al. (U.S. Pat. No. 5,466,574), and
Terstappen et al. (U.S. Pat. No. 6,623,983), the content of each of
which is incorporated by reference herein in its entirety.
[0044] In certain embodiments, the magnetic capture is achieved at
high efficiency by utilizing a flow-through capture cell with a
number of strong rare earth bar magnets placed perpendicular to the
flow of the sample. When using a flow chamber with flow path
cross-section 0.5 mm.times.20 mm (h.times.w) and 7 bar NdFeB
magnets, the flow rate could be as high as 5 mL/min or more, while
achieving capture efficiency close to 100%.
[0045] The above described type of magnetic separation produces
efficient capture of a target analyte and the removal of a majority
of the remaining components of a sample mixture. However, such a
process produces a sample that contains a very high percent of
magnetic particles that are not bound to target analytes because
the magnetic particles are typically added in excess, as well as
non-specific target entities. Non-specific target entities may for
example be bound at a much lower efficiency, for example 1% of the
surface area, while a target of interest might be loaded at 50% or
nearly 100% of the available surface area or available antigenic
cites. However, even 1% loading may be sufficient to impart force
necessary for trapping in a magnetic gradient flow cell or sample
chamber.
[0046] For example, in the case of immunomagnetic binding of
bacteria or fungi in a blood sample, the sample may include: bound
targets at a concentration of about 1/mL or a concentration less
than about 10.sup.6/mL; background particles at a concentration of
about 10.sup.7/ml to about 10.sup.10/ml; and non-specific targets
at a concentration of about 10/ml to about 10.sup.5/ml.
[0047] The presence of magnetic particles that are not bound to
target analytes and non-specific target entities on the surface
that includes the target/magnetic particle complexes interferes
with the ability to successfully detect the target of interest. The
magnetic capture of the resulting mix, and close contact of
magnetic particles with each other and bound targets, result in the
formation of aggregate that is hard to dispense and which might be
resistant or inadequate for subsequent processing or analysis
steps. In order to remove magnetic particles that are not bound to
target analytes and non-specific target entities, the surface may
be washed with a wash solution that reduces particle aggregation,
thereby isolating target/magnetic particle complexes from the
magnetic particles that are not bound to target analytes and
non-specific target entities. The wash solution minimizes the
formation of the aggregates.
[0048] Any wash solution that imparts a net negative charge to the
magnetic particle that is not sufficient to disrupt interaction
between the target-specific moiety of the magnetic particle and the
target analyte may be used. Without being limited by any particular
theory or mechanism of action, it is believed that attachment of
the negatively charged molecules in the wash solution to magnetic
particles provides net negative charge to the particles and
facilitates dispersal of non-specifically aggregated particles. At
the same time, the net negative charge is not sufficient to disrupt
strong interaction between the target-specific moiety of the
magnetic particle and the target analyte (e.g., an antibody-antigen
interaction). Exemplary solutions include heparin, Tris-HCl,
Tris-borate-EDTA (TBE), Tris-acetate-EDTA (TAE), Tris-cacodylate,
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid), PBS
(phosphate buffered saline), PIPES
(piperazine-N,N'-bis(2-ethanesulfonic acid), MES
(2-N-morpholino)ethanesulfonic acid), Tricine
(N-(Tri(hydroximethyl)methyl)glycine), and similar buffering
agents. In certain embodiments, only a single wash cycle is
performed. In other embodiments, more than one wash cycle is
performed.
[0049] In particular embodiments, the wash solution includes
heparin. For embodiments in which the body fluid sample is blood,
the heparin also reduces probability of clotting of blood
components after magnetic capture. The bound targets are washed
with heparin-containing buffer 1-3 times to remove blood components
and to reduce formation of aggregates.
[0050] Once the target/magnetic particle complexes are isolated,
the target may be analyzed by a multitude of existing technologies,
such as miniature NMR , Polymerase Chain Reaction (PCR), mass
spectrometry, fluorescent labeling and visualization using
microscopic observation, fluorescent in situ hybridization (FISH),
growth-based antibiotic sensitivity tests, and variety of other
methods that may be conducted with purified target without
significant contamination from other sample components. In one
embodiment, isolated bacteria are lysed with a chaotropic solution,
and DNA is bound to DNA extraction resin. After washing of the
resin, the bacterial DNA is eluted and used in quantitative RT-PCR
to detect the presence of a specific species, and/or, subclasses of
bacteria.
[0051] In another embodiment, captured bacteria is removed from the
magnetic particles to which they are bound and the processed sample
is mixed with fluorescent labeled antibodies specific to the
bacteria or fluorescent Gram stain. After incubation, the reaction
mixture is filtered through 0.2 .mu.m to 1.0 .mu.m filter to
capture labeled bacteria while allowing majority of free particles
and fluorescent labels to pass through the filter. Bacteria is
visualized on the filter using microscopic techniques, e.g. direct
microscopic observation, laser scanning or other automated methods
of image capture. The presence of bacteria is detected through
image analysis. After the positive detection by visual techniques,
the bacteria can be further characterized using PCR or genomic
methods.
[0052] Detection of bacteria of interest can be performed by use of
nucleic acid probes following procedures which are known in the
art. Suitable procedures for detection of bacteria using nucleic
acid probes are described, for example, in Stackebrandt et al.
(U.S. Pat. No. 5,089,386), King et al. (WO 90/08841), Foster et al.
(WO 92/15883), and Cossart et al. (WO 89/06699), each of which is
hereby incorporated by reference.
[0053] A suitable nucleic acid probe assay generally includes
sample treatment and lysis, hybridization with selected probe(s),
hybrid capture, and detection. Lysis of the bacteria is necessary
to release the nucleic acid for the probes. The nucleic acid target
molecules are released by treatment with any of a number of lysis
agents, including alkali (such as NaOH), guanidine salts (such as
guanidine thiocyanate), enzymes (such as lysozyme, mutanolysin and
proteinase K), and detergents. Lysis of the bacteria, therefore,
releases both DNA and RNA, particularly ribosomal RNA and
chromosomal DNA both of which can be utilized as the target
molecules with appropriate selection of a suitable probe. Use of
rRNA as the target molecule(s), may be advantageous because rRNAs
constitute a significant component of cellular mass, thereby
providing an abundance of target molecules. The use of rRNA probes
also enhances specificity for the bacteria of interest, that is,
positive detection without undesirable cross-reactivity which can
lead to false positives or false detection.
[0054] Hybridization includes addition of the specific nucleic acid
probes. In general, hybridization is the procedure by which two
partially or completely complementary nucleic acids are combined,
under defined reaction conditions, in an anti-parallel fashion to
form specific and stable hydrogen bonds. The selection or
stringency of the hybridization/reaction conditions is defined by
the length and base composition of the probe/target duplex, as well
as by the level and geometry of mis-pairing between the two nucleic
acid strands. Stringency is also governed by such reaction
parameters as temperature, types and concentrations of denaturing
agents present and the type and concentration of ionic species
present in the hybridization solution.
[0055] The hybridization phase of the nucleic acid probe assay is
performed with a single selected probe or with a combination of
two, three or more probes. Probes are selected having sequences
which are homologous to unique nucleic acid sequences of the target
organism. In general, a first capture probe is utilized to capture
formed hybrid molecules. The hybrid molecule is then detected by
use of antibody reaction or by use of a second detector probe which
may be labelled with a radioisotope (such as phosphorus-32) or a
fluorescent label (such as fluorescein) or chemiluminescent
label.
[0056] Detection of bacteria of interest can also be performed by
use of PCR techniques. A suitable PCR technique is described, for
example, in Verhoef et al. (WO 92/08805). Such protocols may be
applied directly to the bacteria captured on the magnetic
particles. The bacteria is combined with a lysis buffer and
collected nucleic acid target molecules are then utilized as the
template for the PCR reaction.
[0057] For detection of the selected bacteria by use of antibodies,
isolated bacteria are contacted with antibodies specific to the
bacteria of interest. As noted above, either polyclonal or
monoclonal antibodies can be utilized, but in either case have
affinity for the particular bacteria to be detected. These
antibodies, will adhere/bind to material from the specific target
bacteria. With respect to labeling of the antibodies, these are
labeled either directly or indirectly with labels used in other
known immunoassays. Direct labels may include fluorescent,
chemiluminescent, bioluminescent, radioactive, metallic, biotin or
enzymatic molecules. Methods of combining these labels to
antibodies or other macromolecules are well known to those in the
art. Examples include the methods of Hijmans, W. et al. (1969),
Clin. Exp. Immunol. 4, 457-, for fluorescein isothiocyanate, the
method of Goding, J. W. (1976), J. Immunol. Meth. 13, 215-, for
tetramethylrhodamine isothiocyanate, and the method of Ingrall, E.
(1980), Meth. in Enzymol. 70, 419-439 for enzymes.
[0058] These detector antibodies may also be labeled indirectly. In
this case the actual detection molecule is attached to a secondary
antibody or other molecule with binding affinity for the
anti-bacteria cell surface antibody. If a secondary antibody is
used it is preferably a general antibody to a class of antibody
(IgG and IgM) from the animal species used to raise the
anti-bacteria cell surface antibodies. For example, the second
antibody may be conjugated to an enzyme, either alkaline
phosphatase or to peroxidase. To detect the label, after the
bacteria of interest is contacted with the second antibody and
washed, the isolated component of the sample is immersed in a
solution containing a chromogenic substrate for either alkaline
phosphatase or peroxidase. A chromogenic substrate is a compound
that can be cleaved by an enzyme to result in the production of
some type of detectable signal which only appears when the
substrate is cleaved from the base molecule. The chromogenic
substrate is colorless, until it reacts with the enzyme, at which
time an intensely colored product is made. Thus, material from the
bacteria colonies adhered to the membrane sheet will become an
intense blue/purple/black color, or brown/red while material from
other colonies will remain colorless. Examples of detection
molecules include fluorescent substances, such as
4-methylumbelliferyl phosphate, and chromogenic substances, such as
4-nitrophenylphosphate, 3,3',5,5'-tetramethylbenzidine and
2,2'-azino-di-[3-ethelbenz-thiazoliane sulfonate (6)]. In addition
to alkaline phosphatase and peroxidase, other useful enzymes
include .beta.-galactosidase, .beta.-glucuronidase,
.alpha.-glucosidase, .beta.-glucosidase, .alpha.-mannosidase,
galactose oxidase, glucose oxidase and hexokinase.
[0059] Detection of bacteria of interest using NMR may be
accomplished as follows. In the use of NMR as a detection
methodology, in which a sample is delivered to a detector coil
centered in a magnet, the target of interest, such as a
magnetically labeled bacterium, may be delivered by a fluid medium,
such as a fluid substantially composed of water. In such a case,
the magnetically labeled target may go from a region of very low
magnetic field to a region of high magnetic field, for example, a
field produced by an about 1 to about 2 Tesla magnet. In this
manner, the sample may traverse a magnetic gradient, on the way
into the magnet and on the way out of the magnet. As may be seen
via equations 1 and 2 below, the target may experience a force
pulling into the magnet in the direction of sample flow on the way
into the magnet, and a force into the magnet in the opposite
direction of flow on the way out of the magnet. The target may
experience a retaining force trapping the target in the magnet if
flow is not sufficient to overcome the gradient force.
m dot (del B)=F Equation 1
v.sub.t=-F/(6*p*n*r) Equation 2
where n is the viscosity, r is the particle diameter, F is the
vector force, B is the vector field, and m is the vector moment of
the particle.
[0060] Magnetic fields on a path into a magnet may be non-uniform
in the transverse direction with respect to the flow into the
magnet. As such, there may be a transverse force that pulls targets
to the side of a container or a conduit that provides the sample
flow into the magnet. Generally, the time it takes a target to
reach the wall of a conduit is associated with the terminal
velocity and is lower with increasing viscosity. The terminal
velocity is associated with the drag force, which may be indicative
of creep flow in certain cases. In general, it may be advantageous
to have a high viscosity to provide a higher drag force such that a
target will tend to be carried with the fluid flow through the
magnet without being trapped in the magnet or against the conduit
walls.
[0061] Newtonian fluids have a flow characteristic in a conduit,
such as a round pipe, for example, that is parabolic, such that the
flow velocity is zero at the wall, and maximal at the center, and
having a parabolic characteristic with radius. The velocity
decreases in a direction toward the walls, and it is easier to
magnetically trap targets near the walls, either with transverse
gradients force on the target toward the conduit wall, or in
longitudinal gradients sufficient to prevent target flow in the
pipe at any position. In order to provide favorable fluid drag
force to keep the samples from being trapped in the conduit, it may
be advantageous to have a plug flow condition, wherein the fluid
velocity is substantially uniform as a function of radial position
in the conduit.
[0062] When NMR detection is employed in connection with a flowing
sample, the detection may be based on a perturbation of the NMR
water signal caused by a magnetically labeled target (Sillerud et
al., JMR (Journal of Magnetic Resonance), vol. 181, 2006). In such
a case, the sample may be excited at time 0, and after some delay,
such as about 50 ms or about 100 ms, an acceptable measurement
(based on a detected NMR signal) may be produced. Alternatively,
such a measurement may be produced immediately after excitation,
with the detection continuing for some duration, such as about 50
ms or about 100 ms. It may be advantageous to detect the NMR signal
for substantially longer time durations after the excitation.
[0063] By way of example, the detection of the NMR signal may
continue for a period of about 2 seconds in order to record
spectral information at high-resolution. In the case of parabolic
or Newtonian flow, the perturbation excited at time 0 is typically
smeared because the water around the perturbation source travels at
different velocity, depending on radial position in the conduit. In
addition, spectral information may be lost due to the smearing or
mixing effects of the differential motion of the sample fluid
during signal detection. When carrying out an NMR detection
application involving a flowing fluid sample, it may be
advantageous to provide plug-like sample flow to facilitate
desirable NMR contrast and/or desirable NMR signal detection.
[0064] Differential motion within a flowing Newtonian fluid may
have deleterious effects in certain situations, such as a situation
in which spatially localized NMR detection is desired, as in
magnetic resonance imaging. In one example, a magnetic object, such
as a magnetically labeled bacterium, is flowed through the NMR
detector and its presence and location are detected using MRI
techniques. The detection may be possible due to the magnetic field
of the magnetic object, since this field perturbs the magnetic
field of the fluid in the vicinity of the magnetic object. The
detection of the magnetic object is improved if the fluid near the
object remains near the object. Under these conditions, the
magnetic perturbation may be allowed to act longer on any given
volume element of the fluid, and the volume elements of the fluid
so affected will remain in close spatial proximity. Such a
stronger, more localized magnetic perturbation will be more readily
detected using NMR or MRI techniques.
[0065] If a Newtonian fluid is used to carry the magnetic objects
through the detector, the velocity of the fluid volume elements
will depend on radial position in the fluid conduit. In such a
case, the fluid near a magnetic object will not remain near the
magnetic object as the object flows through the detector. The
effect of the magnetic perturbation of the object on the
surrounding fluid may be smeared out in space, and the strength of
the perturbation on any one fluid volume element may be reduced
because that element does not stay within range of the
perturbation. The weaker, less-well-localized perturbation in the
sample fluid may be undetectable using NMR or MRI techniques.
[0066] Certain liquids, or mixtures of liquids, exhibit
non-parabolic flow profiles in circular conduits. Such fluids may
exhibit non-Newtonian flow profiles in other conduit shapes. The
use of such a fluid may prove advantageous as the detection fluid
in an application employing an NMR-based detection device. Any such
advantageous effect may be attributable to high viscosity of the
fluid, a plug-like flow profile associated with the fluid, and/or
other characteristic(s) attributed to the fluid that facilitate
detection. As an example, a shear-thinning fluid of high viscosity
may exhibit a flow velocity profile that is substantially uniform
across the central regions of the conduit cross-section. The
velocity profile of such a fluid may transition to a zero or very
low value near or at the walls of the conduit, and this transition
region may be confined to a very thin layer near the wall.
[0067] Not all fluids, or all fluid mixtures, are compatible with
the NMR detection methodology. In one example, a mixture of
glycerol and water can provide high viscosity, but the NMR
measurement is degraded because separate NMR signals are detected
from the water and glycerol molecules making up the mixture. This
can undermine the sensitivity of the NMR detector. In another
example, the non-water component of the fluid mixture can be chosen
to have no NMR signal, which may be achieved by using a
perdeuterated fluid component, for example, or using a
perfluorinated fluid component. This approach may suffer from the
loss of signal intensity since a portion of the fluid in the
detection coil does not produce a signal.
[0068] Another approach may be to use a secondary fluid component
that constitutes only a small fraction of the total fluid mixture.
Such a low-concentration secondary fluid component can produce an
NMR signal that is of negligible intensity when compared to the
signal from the main component of the fluid, which may be water. It
may be advantageous to use a low-concentration secondary fluid
component that does not produce an NMR signal in the detector. For
example, a perfluorinated or perdeuterated secondary fluid
component may be used. The fluid mixture used in the NMR detector
may include one, two, or more than two secondary components in
addition to the main fluid component. The fluid components employed
may act in concert to produce the desired fluid flow
characteristics, such as high-viscosity and/or plug flow. The fluid
components may be useful for providing fluid characteristics that
are advantageous for the performance of the NMR detector, for
example by providing NMR relaxation times that allow faster
operation or higher signal intensities.
[0069] A non-Newtonian fluid may provide additional advantages for
the detection of objects by NMR or MRI techniques. As one example,
the objects being detected may all have substantially the same
velocity as they go through the detection coil. This characteristic
velocity may allow simpler or more robust algorithms for the
analysis of the detection data. As another example, the objects
being detected may have fixed, known, and uniform velocity. This
may prove advantageous in devices where the position of the
detected object at later times is needed, such as in a device that
has a sequestration chamber or secondary detection chamber
down-stream from the NMR or MRI detection coil, for example.
[0070] In an exemplary embodiment, sample delivery into and out of
a 1.7 T cylindrical magnet using a fluid delivery medium containing
0.1% to 0.5% Xanthan gum in water was successfully achieved. Such
delivery is suitable to provide substantially plug-like flow, high
viscosity, such as from about 10 cP to about 3000 cP, and good NMR
contrast in relation to water. Xanthan gum acts as a non-Newtonian
fluid, having characteristics of a non-Newtonian fluid that are
well know in the art, and does not compromise NMR signal
characteristics desirable for good detection in a desirable mode of
operation.
[0071] In certain embodiments, methods of the invention are useful
for direct detection of bacteria from blood. Such a process is
described here. Sample is collected in sodium heparin tube by
venipuncture, acceptable sample volume is about 1 mL to 10 mL.
Sample is diluted with binding buffer and superparamagnetic
particles having target-specific binding moieties are added to the
sample, followed by incubation on a shaking incubator at 37.degree.
C. for about 30 min to 120 min. Alternative mixing methods can also
be used. In a particular embodiment, sample is pumped through a
static mixer, such that reaction buffer and magnetic particles are
added to the sample as the sample is pumped through the mixer. This
process allows for efficient integration of all components into a
single fluidic part, avoids moving parts and separate incubation
vessels and reduces incubation time.
[0072] Capture of the labeled targets allows for the removal of
blood components and reduction of sample volume from 30 mL to 5 mL.
The capture is performed in a variety of magnet/flow
configurations. In certain embodiments, methods include capture in
a sample tube on a shaking platform or capture in a flow-through
device at flow rate of 5 mL/min, resulting in total capture time of
6 min.
[0073] After capture, the sample is washed with wash buffer
including heparin to remove blood components and free particles.
The composition of the wash buffer is optimized to reduce
aggregation of free particles, while maintaining the integrity of
the particle/target complexes.
[0074] The detection method is based on a miniature NMR detector
tuned to the magnetic resonance of water. When the sample is
magnetically homogenous (no bound targets), the NMR signal from
water is clearly detectable and strong. The presence of magnetic
material in the detector coil disturbs the magnetic field,
resulting in reduction in water signal. One of the primary benefits
of this detection method is that there is no magnetic background in
biological samples which significantly reduces the requirements for
stringency of sample processing. In addition, since the detected
signal is generated by water, there is a built-in signal
amplification which allows for the detection of a single labeled
bacterium.
INCORPORATION BY REFERENCE
[0075] References and citations to other documents, such as
patents, patent applications, patent publications, journals, books,
papers, web contents, have been made throughout this disclosure.
All such documents are hereby incorporated herein by reference in
their entirety for all purposes.
EQUIVALENTS
[0076] Various modifications of the invention and many further
embodiments thereof, in addition to those shown and described
herein, will become apparent to those skilled in the art from the
full contents of this document, including references to the
scientific and patent literature cited herein. The subject matter
herein contains important information, exemplification and guidance
that can be adapted to the practice of this invention in its
various embodiments and equivalents thereof.
EXAMPLES
Example 1
Sample
[0077] Blood samples from healthy volunteers were spiked with
clinically relevant concentrations of bacteria (1-10 CFU/mL)
including both laboratory strains and clinical isolates of the
bacterial species most frequently found in bloodstream
infections.
Example 2
Antibody Preparation
[0078] In order to generate polyclonal, pan-Gram-positive
bacteria-specific IgG, a goat was immunized by first administering
bacterial antigens suspended in complete Freund's adjuvant intra
lymph node, followed by subcutaneous injection of bacterial
antigens in incomplete Freund's adjuvant in 2 week intervals. The
antigens were prepared for antibody production by growing bacteria
to exponential phase (OD.sub.600=0.4-0.8). Following harvest of the
bacteria by centrifugation, the bacteria was inactivated using
formalin fixation in 4% formaldehyde for 4 hr at 37.degree. C.
After 3 washes of bacteria with PBS (15 min wash, centrifugation
for 20 min at 4000 rpm) the antigen concentration was measured
using BCA assay and the antigen was used at 1 mg/mL for
immunization. In order to generate Gram-positive bacteria-specific
IgG, several bacterial species were used for inoculation:
Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus
faecium and Enterococcus fecalis.
[0079] The immune serum was purified using affinity chromatography
on a protein G sepharose column (GE Healthcare), and reactivity was
determined using ELISA. Antibodies cross-reacting with
Gram-negative bacteria and fungi were removed by absorption of
purified IgG with formalin-fixed Gram-negative bacteria and fungi.
The formalin-fixed organisms were prepared similar to as described
above and mixed with IgG. After incubation for 2 hrs at room
temperature, the preparation was centrifuged to remove bacteria.
Final antibody preparation was clarified by centrifugation and used
for the preparation of antigen-specific magnetic particles.
[0080] Pan-Gram-negative IgG were generated in a similar fashion
using inactivated Enterobacter cloacae, Pseudomonas aeruginosa,
Serratia marcescens and other gram-negative bacteria as immunogens.
The IgG fraction of serum was purified using protein-G affinity
chromatography as described above.
[0081] Similarly, target specific antibodies were generated by
inoculation of goats using formalin-fixed bacteria, immunization
was performed with 2 or more closely related organisms.
Example 3
Preparation of Antigen-Specific Magnetic Particles
[0082] Superparamagnetic particles were synthesized by
encapsulating iron oxide nanoparticles (5-15 nm diameter) in a
latex core and labeling with goat IgG. Ferrofluid containing
nanoparticles in organic solvent was precipitated with ethanol,
nanoparticles were resuspended in aqueous solution of styrene and
surfactant Hitenol BC-10, and emulsified using sonication. The
mixture was allowed to equilibrate overnight with stirring and
filtered through 1.2 and 0.45 .mu.m filters to achieve uniform
micelle size. Styrene, acrylic acid and divynilbenzene were added
in carbonate buffer at pH 9.6. The polymerization was initiated in
a mixture at 70.degree. C. with the addition of
K.sub.2S.sub.2O.sub.8 and the reaction was allowed to complete
overnight. The synthesized particles were washed 3 times with 0.1%
SDS using magnetic capture, filtered through 1.2, 0.8, and 0.45
.mu.tm filters and used for antibody conjugation.
[0083] The production of particles resulted in a distribution of
sizes that may be characterized by an average size and a standard
deviation. In the case of labeling and extracting of bacteria from
blood, the average size for optmal performance was found to be
between 100 and 350 nm, for example between 200 nm to 250 nm.
[0084] The purified IgG were conjugated to prepared particles using
standard EDC/sulfo-NHS chemistry. After conjugation, the particles
were resuspended in 0.1% BSA which is used to block non-specific
binding sites on the particle and to increase the stability of
particle preparation.
Example 4
Labeling of Rare Cells Using Excess of Magnetic Nanoparticles
[0085] Bacteria, present in blood during blood-stream infection,
were magnetically labeled using the superparamagnetic particles
prepared in Example 3 above. The spiked samples as described in
Example 1 were diluted 3-fold with a Tris-based binding buffer and
target-specific particles, followed by incubation on a shaking
platform at 37.degree. C. for up to 2 hr. The optimal concentration
of particles was determined by titration and was found to be in the
range between 1.times.10.sup.8 and 5.times.10.sup.10 particle/mL.
After incubation, the labeled targets were magnetically separated
followed by a wash step designed to remove blood products. See
example 5 below.
Example 5
Magnetic Capture of Bound Bacteria
[0086] Blood including the magnetically labeled target bacteria and
excess free particles were injected into a flow-through capture
cell with a number of strong rare earth bar magnets placed
perpendicular to the flow of the sample. With using a flow chamber
with flow path cross-section 0.5 mm.times.20 mm (h.times.w) and 7
bar NdFeB magnets, a flow rate as high as 5 mL/min was achieved.
After flowing the mixture through the channel in the presence of
the magnet, a wash solution including heparin was flowed through
the channel. The bound targets were washed with heparin-containing
buffer one time to remove blood components and to reduce formation
of magnetic particle aggregates. In order to effectively wash bound
targets, the magnet was removed and captured magnetic material was
resuspended in wash buffer, followed by reapplication of the
magnetic field and capture of the magnetic material in the same
flow-through capture cell.
[0087] Removal of the captured labeled targets was possible after
moving magnets away from the capture chamber and eluting with flow
of buffer solution.
* * * * *